Eliminate Antibody Purification Bottlenecks With New, Protein A Membrane Technology

By William C. Barrett, Ph.D. and Eric Van Voorhees, MS Gore PharmBIO Products

Today, therapeutic antibodies make up a growing portion of new drugs in development and receiving regulatory approvals. They are an important option for treating many cancers, infectious diseases such as COVID-19, and many other conditions.

According to Global Market Insights Inc., the global antibody therapy market is projected to reach $445 billion by 2028.¹ In addition to the development of traditional monoclonal antibodies, there are also advances in new antibody-based therapies such as bispecific antibodies, fragments, and Fc-fusion proteins, many of which are being developed for more targeted, smaller populations. The result is more molecules manufactured in smaller batch sizes.

To streamline drug development and enable a wider variety of molecules, the industry is recognizing the need for bioprocessing that is more cost effective, efficient, and versatile. To meet these needs, it is critical to address the protein capture step of downstream purification, so Gore developed a new membrane-based, Protein-A affinity chromatography technology.